EUVIMEDEUVIMED entdecken
Crossref

Novel metallo‐β‐lactamases inhibitors restore the susceptibility of carbapenems to New Delhi metallo‐lactamase‐1 (NDM‐1)‐harbouring bacteria

Yan Guo, Hongtao Liu, Mengge Yang, Rui Ding, Yawen Gao, Xiaodi Niu, Xuming Deng, Jianfeng Wang iD, Haihua Feng iD, Jiazhang Qiu iD

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.16210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Yan Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Educ…. Hauptthemen laut MEDLINE: Carbapenems, Dexrazoxane. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Interdisciplinary Integration and Innovation Project of JLU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose The production of metallo‐β‐lactamases is a major mechanisms adopted by bacterial pathogens to resist carbapenems. Repurposing approved drugs to restore the efficacy of carbapenems represents an efficient and cost‐effective approach to fight infections caused by carbapenem resistant pathogens. Experimental approach The nitrocefin hydrolysis assay was employed to screen potential New Delhi metallo‐lactamase‐1 (NDM‐1) inhibitors from a commercially available U.S. Food and Drug Administration (FDA) approved drug library. The mechanism of inhibition was clarified by metal restoration, inductively coupled plasma mass spectrometry (ICP‐MS) and molecular dynamics simulation. The in vitro synergistic antibacterial effect of the identified inhibitors with meropenem was determined by the checkerboard minimum inhibitory concentration (MIC) assay, time‐dependent killing assay and combined disc test. Three mouse infection models were used to further evaluate the in vivo therapeutic efficacy of combined therapy. Key results Twelve FDA‐approved compounds were initially screened to inhibit the ability of NDM‐1 to hydrolyse nitrocefin. Among these compounds, dexrazoxane, embelin, candesartan cilexetil and nordihydroguaiaretic acid were demonstrated to inhibit all tested metallo‐β‐lactamases and showed an in vitro synergistic bactericidal effect with meropenem against metallo‐β‐lactamases‐producing bacteria. Dexrazoxane, embelin and candesartan cilexetil are metal ion chelating agents, while the inhibition of NDM‐1 by nordihydroguaiaretic acid involves its direct binding to the active region of NDM‐1. Furthermore, these four drugs dramatically rescued the treatment efficacy of meropenem in three infection models. Conclusions and implications Our observations indicated that dexrazoxane, embelin, candesartan cilexetil and nordihydroguaiaretic acid are promising carbapenem adjuvants against metallo‐β‐lactamases‐positive carbapenem resistant bacterial pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarbapenemsDexrazoxaneAnimalsMiceMeropenembeta-Lactamase InhibitorsMasoprocolAnti-Bacterial Agentsbeta-LactamasesBacteriaMicrobial Sensitivity TestsCephalosporinsBenzimidazolesBiphenyl CompoundsTetrazolesBenzoquinones

Stichwörter der Autor:innen

FDA-approved drug librarycarbapenem-resistant gram-negative bacteriacarbapenemsdrug repurposingmetallo-β-lactamase

Substanzen

CarbapenemsMeropenembeta-Lactamase InhibitorsMasoprocolDexrazoxaneAnti-Bacterial Agentsbeta-LactamasesnitrocefinCephalosporinsbeta-lactamase NDM-1

Autor:innen und Institutionen

  • State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, College of Veterinary Medicine, Jilin University, Changchun, Ch…
  • College of Food Science and Engineering, Jilin University, Changchun, Jilin, China.

ORCID-Profile: Jianfeng Wang, Haihua Feng, Jiazhang Qiu

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Interdisciplinary Integration and Innovation Project of JLU
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Guo, Y., Liu, H., Yang, M., Ding, R., Gao, Y., Niu, X., Deng, X., Wang, J., Feng, H., & Qiu, J. (2024). Novel metallo‐β‐lactamases inhibitors restore the susceptibility of carbapenems to New Delhi metallo‐lactamase‐1 (NDM‐1)‐harbouring bacteria. British Journal of Pharmacology. https://doi.org/10.1111/bph.16210

Vancouver

Guo Y, Liu H, Yang M, Ding R, Gao Y, Niu X, et al. Novel metallo‐β‐lactamases inhibitors restore the susceptibility of carbapenems to New Delhi metallo‐lactamase‐1 (NDM‐1)‐harbouring bacteria. British Journal of Pharmacology. 2024. doi:10.1111/bph.16210

BibTeX
@article{Guo2024,
  author = {Guo, Yan and Liu, Hongtao and Yang, Mengge and Ding, Rui and Gao, Yawen and Niu, Xiaodi and Deng, Xuming and Wang, Jianfeng and Feng, Haihua and Qiu, Jiazhang},
  title = {Novel metallo‐β‐lactamases inhibitors restore the susceptibility of carbapenems to New Delhi metallo‐lactamase‐1 (NDM‐1)‐harbouring bacteria},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16210}
}
Kostenlos starten →